Catalent bringing clinical supply services to Japanese facility

By Dan Stanton contact

- Last updated on GMT

Image: iStock/Flaz81
Image: iStock/Flaz81

Related tags: Japan

Catalent will expand its cGMP facility in Japan to bring secondary packaging and clinical supply services to the region.

The 200,000 sq. ft. cGMP facility in Kakegawa, Japan has been operating for over 40 years, providing a range of manufacturing services.

Now Catalent intends to offer local and regional customers clinical supply services direct from the site.

“We previously performed any necessary packaging work at a Catalent facility outside of the region and then imported the finished goods into an in-country depot for distribution to our customers' clinical sites within Japan,”​ Amy Lombardi, Group Product Manager, Catalent Clinical Supply Services, told Outsourcing-Pharma.com.

“Having a facility in Japan that offers secondary packaging, along with clinical storage and distribution services, offers our customers greater flexibility and improves supply chain efficiency.”  

The site will form part of the New Jersey, US-headquartered firm’s Asian-Pacific clinical supply network, which includes a full service clinical packaging facility in Shanghai, cold-chain and secondary packaging and clinical storage facility in Singapore.

“This investment boosts a critical part of our business capabilities in Asia-Pacific by adding the ability to support global and local pharma companies' clinical trial needs from Japan,”​ Lombardi continued.

“It will provide local capabilities, with dedicated local resources and expertise, to better serve multinational customers' Japanese studies and Japanese pharma's global studies, in addition to domestic only studies.”

Lombardi did not divulge financial details or whether the expansion would create any new jobs.

Catalent in Japan

The announcement is the latest in a line of recent investments in Japan by the contract development and manufacturing organisation (CDMO).

In 2014​, Catalent announced it was opening an oral formulation development lab and expanding its OptiGel micro softgel manufacturing capacity at the Kakegawa site.

The firm has also been forging a number of biologics R&D partnerships in the region, including an agreement with the Center for iPS (induced pluripotent stem) Cell Research and Application (CiRA)​ at Kyoto University and teamed up with Mitsubishi Gas Chemical Company​ to make cell lines for the region.

Related news

Show more

Related products

show more

Import Risks & Clinical Supply Depots

Import Risks & Clinical Supply Depots

Catalent Pharma Solutions | 07-Nov-2018 | Case Study

A sponsor running a clinical trial in Israel arranged to ship their clinical trial product from Europe to a depot in Israel. With the protocol based in...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Discover Fermion’s new API unit 4 in Hanko

Discover Fermion’s new API unit 4 in Hanko

Recorded the 04-Sep-2018 | Webinar

Join this webinar to learn more about Fermion’s new manufacturing unit 4 at the Hanko site. This webinar will provide virtual tour to our new state of...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars